Drugs.com - Clinical Trials

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

CULVER CITY, Calif.–(BUSINESS WIRE)–Jun. 2, 2025– ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the...

Jun 3, 2025 - 22:55
 0
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
CULVER CITY, Calif.–(BUSINESS WIRE)–Jun. 2, 2025– ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the...
Read More

Tags:

Previous Article

Early Results from Johnson & Johnson’s Trispecific Antibody JNJ-5322 Show Promis...

Next Article

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIG...

Related Posts

Rilzabrutinib Granted Orphan Drug Designation in the US for Sickle Cell Disease

Rilzabrutinib Granted Orphan Drug Designation in the US...

Jun 3, 2025  0

Johnson & Johnson Unveils First-in-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer

Johnson & Johnson Unveils First-in-Human Results for Pa...

Jun 3, 2025  0

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Receives U.S. FDA Fast Track Designa...

May 12, 2025  0